HC Wainwright assumes AnaptysBio at Buy, sets $95 target
HC Wainwright & Co. analyst Joseph Pantginis assumed coverage of AnaptysBio with a Buy rating and a price target of $95.
*this image is generated using AI for illustrative purposes only.
HC Wainwright & Co. analyst Joseph Pantginis has assumed coverage of AnaptysBio with a Buy rating and established a price target of $95. The rating reflects a positive outlook on the company's stock performance.
Analyst Details
The recommendation comes from Joseph Pantginis, an analyst at HC Wainwright & Co. The firm's price target of $95 provides a specific valuation benchmark for investors evaluating AnaptysBio.
| Analyst | Firm | Rating | Price Target |
|---|---|---|---|
| Joseph Pantginis | HC Wainwright & Co. | Buy | $95 |
AnaptysBio trades on the NASDAQ under the ticker symbol ANAB.
What upcoming clinical milestones could drive AnaptysBio's stock toward the $95 price target?
How does this Buy rating compare to the consensus view of other analysts covering ANAB?
What competitive landscape factors might impact AnaptysBio's ability to meet this valuation?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
